Glikációs végtermékek kimutatása diabetes mellitusban szenvedö betegek vizeletében.

Translated title of the contribution: Detection of glycation end products in the urine of diabetic patients

I. Wittmann, Z. Wagner, L. Pótó, L. Wágner, I. Mazák, J. Nagy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Advanced glycation end products play an important role in the development of tissue damage in diabetes mellitus. The aim of the present study was the investigation of the excretion of different glycation end products in the urine. Methylglyoxal, an intermediate product of the glycation, formed with L-arginine in an in vitro model two fluorescent peaks. These peaks can be characteristic for imidazolone-like product(s) which are produced also in the reaction of methylglyoxal with proteins described in the literature, suggesting modification of proteins with methylglyoxal at the guanidino group of the L-arginine amino acid. Using the fluorescent characteristics of these (excitation/emission: 320/400 nm and 340/425 nm) and the generally accepted wavelength of the so called non-specific advanced glycation end product (370/440 nm) could be identified these glycation end products in the urine of 98 patients with diabetes mellitus (21 type I., 77 type II., 51 female and 47 male, mean age: 56.6 years). These three particular glycation end products showed significant intercorrelations in the urine (p <0.001). Concentrations of these glycation end products in the urine correlated negatively with the serum creatinine in the range between 120-240 mumol/l (p <0.001). Data presented here verify that non-specific glycation end product and imidazolone-like glycation end products can be detected in the urine of diabetic patients. Elimination of these products by the urine is markedly decreased in the stage of early renal insufficiency. These decrease in the secretion can cause an elevation of the advanced glycation end products in the circulation leading progression of diabetic complication.

Original languageHungarian
Pages (from-to)1997-2001
Number of pages5
JournalOrvosi Hetilap
Volume140
Issue number36
Publication statusPublished - Sep 5 1999

Fingerprint

Urine
Pyruvaldehyde
Advanced Glycosylation End Products
Arginine
Diabetes Complications
Type 1 Diabetes Mellitus
Renal Insufficiency
Creatinine
Diabetes Mellitus
Proteins
Amino Acids
Serum
imidazolone

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Glikációs végtermékek kimutatása diabetes mellitusban szenvedö betegek vizeletében. / Wittmann, I.; Wagner, Z.; Pótó, L.; Wágner, L.; Mazák, I.; Nagy, J.

In: Orvosi Hetilap, Vol. 140, No. 36, 05.09.1999, p. 1997-2001.

Research output: Contribution to journalArticle

@article{061a6e125fc940bd84c633e75df5b0de,
title = "Glik{\'a}ci{\'o}s v{\'e}gterm{\'e}kek kimutat{\'a}sa diabetes mellitusban szenved{\"o} betegek vizelet{\'e}ben.",
abstract = "Advanced glycation end products play an important role in the development of tissue damage in diabetes mellitus. The aim of the present study was the investigation of the excretion of different glycation end products in the urine. Methylglyoxal, an intermediate product of the glycation, formed with L-arginine in an in vitro model two fluorescent peaks. These peaks can be characteristic for imidazolone-like product(s) which are produced also in the reaction of methylglyoxal with proteins described in the literature, suggesting modification of proteins with methylglyoxal at the guanidino group of the L-arginine amino acid. Using the fluorescent characteristics of these (excitation/emission: 320/400 nm and 340/425 nm) and the generally accepted wavelength of the so called non-specific advanced glycation end product (370/440 nm) could be identified these glycation end products in the urine of 98 patients with diabetes mellitus (21 type I., 77 type II., 51 female and 47 male, mean age: 56.6 years). These three particular glycation end products showed significant intercorrelations in the urine (p <0.001). Concentrations of these glycation end products in the urine correlated negatively with the serum creatinine in the range between 120-240 mumol/l (p <0.001). Data presented here verify that non-specific glycation end product and imidazolone-like glycation end products can be detected in the urine of diabetic patients. Elimination of these products by the urine is markedly decreased in the stage of early renal insufficiency. These decrease in the secretion can cause an elevation of the advanced glycation end products in the circulation leading progression of diabetic complication.",
author = "I. Wittmann and Z. Wagner and L. P{\'o}t{\'o} and L. W{\'a}gner and I. Maz{\'a}k and J. Nagy",
year = "1999",
month = "9",
day = "5",
language = "Hungarian",
volume = "140",
pages = "1997--2001",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "36",

}

TY - JOUR

T1 - Glikációs végtermékek kimutatása diabetes mellitusban szenvedö betegek vizeletében.

AU - Wittmann, I.

AU - Wagner, Z.

AU - Pótó, L.

AU - Wágner, L.

AU - Mazák, I.

AU - Nagy, J.

PY - 1999/9/5

Y1 - 1999/9/5

N2 - Advanced glycation end products play an important role in the development of tissue damage in diabetes mellitus. The aim of the present study was the investigation of the excretion of different glycation end products in the urine. Methylglyoxal, an intermediate product of the glycation, formed with L-arginine in an in vitro model two fluorescent peaks. These peaks can be characteristic for imidazolone-like product(s) which are produced also in the reaction of methylglyoxal with proteins described in the literature, suggesting modification of proteins with methylglyoxal at the guanidino group of the L-arginine amino acid. Using the fluorescent characteristics of these (excitation/emission: 320/400 nm and 340/425 nm) and the generally accepted wavelength of the so called non-specific advanced glycation end product (370/440 nm) could be identified these glycation end products in the urine of 98 patients with diabetes mellitus (21 type I., 77 type II., 51 female and 47 male, mean age: 56.6 years). These three particular glycation end products showed significant intercorrelations in the urine (p <0.001). Concentrations of these glycation end products in the urine correlated negatively with the serum creatinine in the range between 120-240 mumol/l (p <0.001). Data presented here verify that non-specific glycation end product and imidazolone-like glycation end products can be detected in the urine of diabetic patients. Elimination of these products by the urine is markedly decreased in the stage of early renal insufficiency. These decrease in the secretion can cause an elevation of the advanced glycation end products in the circulation leading progression of diabetic complication.

AB - Advanced glycation end products play an important role in the development of tissue damage in diabetes mellitus. The aim of the present study was the investigation of the excretion of different glycation end products in the urine. Methylglyoxal, an intermediate product of the glycation, formed with L-arginine in an in vitro model two fluorescent peaks. These peaks can be characteristic for imidazolone-like product(s) which are produced also in the reaction of methylglyoxal with proteins described in the literature, suggesting modification of proteins with methylglyoxal at the guanidino group of the L-arginine amino acid. Using the fluorescent characteristics of these (excitation/emission: 320/400 nm and 340/425 nm) and the generally accepted wavelength of the so called non-specific advanced glycation end product (370/440 nm) could be identified these glycation end products in the urine of 98 patients with diabetes mellitus (21 type I., 77 type II., 51 female and 47 male, mean age: 56.6 years). These three particular glycation end products showed significant intercorrelations in the urine (p <0.001). Concentrations of these glycation end products in the urine correlated negatively with the serum creatinine in the range between 120-240 mumol/l (p <0.001). Data presented here verify that non-specific glycation end product and imidazolone-like glycation end products can be detected in the urine of diabetic patients. Elimination of these products by the urine is markedly decreased in the stage of early renal insufficiency. These decrease in the secretion can cause an elevation of the advanced glycation end products in the circulation leading progression of diabetic complication.

UR - http://www.scopus.com/inward/record.url?scp=0033527121&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033527121&partnerID=8YFLogxK

M3 - Article

VL - 140

SP - 1997

EP - 2001

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 36

ER -